Landmark Lancet Study Finds No Evidence Cannabis Treats Anxiety, Depression, or PTSD
Advertisement
A sweeping new analysis published in The Lancet Psychiatry has delivered what may be the most consequential finding in cannabis research this decade: after reviewing 45 years of clinical evidence, researchers at the University of Sydney concluded that medicinal cannabis shows no meaningful effectiveness for treating anxiety, depression, or post-traumatic stress disorder. The study, led by Dr. Jack Wilson, examined 54 randomized controlled trials conducted between 1980 and 2025, making it the largest systematic review ever undertaken on cannabis and mental health outcomes.
The timing could not be more significant. As cannabis rescheduling [Quick Definition: The federal process of moving cannabis from Schedule I to a less restrictive category] advances at the federal level and more states expand medical programs, millions of Americans are turning to cannabis specifically for mental health relief — often without rigorous evidence to support that choice.
Key Takeaways
- Approximately 27% of US and Canadian adults aged 16-65 use medical cannabis, with half citing mental health as their primary reason
- The largest-ever systematic review of cannabis and mental health, published in The Lancet Psychiatry, found no evidence that cannabis effectively treats anxiety, depression, or PTSD
- Weak evidence suggests potential benefits for insomnia, autism symptoms, Tourette's tics, and cannabis use disorder, but all require further study
Table of Contents
- The Scale of the Problem
- What the Researchers Found
- Where Cannabis Showed Some Promise
- One Clear Warning: Cocaine Use Disorder
- The Implications for Patients and Policy
- The Research Gap That Needs Filling
The Scale of the Problem
The numbers paint a stark picture of how widespread cannabis use for mental health has become. Approximately 27 percent of adults aged 16 to 65 in the United States and Canada report using medical cannabis, and roughly half of those users cite mental health symptom management as their primary reason. That means tens of millions of people across North America are using cannabis-based products to manage conditions like anxiety, depression, and PTSD — conditions for which this new research suggests cannabis provides no reliable benefit.
This is not a fringe behavior driven by stereotypical stoner culture. Medical cannabis for mental health has been recommended by physicians, promoted by dispensaries, and endorsed by patient advocacy groups. State medical marijuana programs across the country list anxiety, PTSD, and depression among qualifying conditions, effectively directing patients toward a treatment that this research calls into question.
What the Researchers Found
Dr. Wilson and his team conducted a systematic review and meta-analysis, the gold standard of medical evidence, examining every available randomized controlled trial testing cannabinoid-based treatments for mental health conditions. Their methodology was rigorous: only studies with proper control groups, randomization, and clinical outcome measures were included.
The central finding was unambiguous. Across the full body of evidence, medicinal cannabis showed no statistically significant benefit for anxiety disorders, major depressive disorder, or PTSD when compared to placebo treatments. The researchers found that any perceived improvements reported by patients were consistent with placebo responses — a well-documented phenomenon in mental health treatment trials where patients experience improvement simply because they believe they are receiving an active treatment.
Dr. Wilson warned that the routine use of medicinal cannabis for mental health could actually be doing more harm than good. He cited the established link between cannabis use and increased risk of psychotic episodes, particularly in individuals predisposed to psychotic disorders.
He also raised concerns about treatment delay — patients who rely on cannabis for anxiety or depression may postpone seeking evidence-based therapies like cognitive behavioral therapy or proven pharmaceutical treatments, potentially worsening their conditions over time.
Where Cannabis Showed Some Promise
The study was not entirely negative. The researchers identified weak but potentially meaningful evidence suggesting cannabis-based treatments might benefit four specific conditions: cannabis use disorder itself, certain symptoms of autism spectrum disorder, insomnia, and tics associated with Tourette's syndrome.
However, Dr. Wilson was careful to characterize the evidence quality for these applications as low. None of these potential benefits met the threshold for a strong clinical recommendation, and the researchers called for larger, more rigorous trials before cannabis could be considered a viable treatment option for any of them.
The insomnia finding is particularly relevant given the enormous consumer market for CBD sleep products. While the review identified some signal of benefit, the evidence was insufficient to recommend cannabis over established sleep interventions, and the researchers noted that the long-term effects of nightly cannabis use on sleep architecture remain poorly understood.
One Clear Warning: Cocaine Use Disorder
The review produced one finding that was both surprising and concerning. Cannabis use appeared to actively worsen outcomes for individuals with cocaine-use disorder, increasing cravings and making recovery more difficult. The researchers stated clearly that cannabis should not be considered as a treatment approach for cocaine dependence under any circumstances.
This finding is particularly important given the growing interest in cannabis as a harm reduction tool for various substance use disorders. While some advocates have promoted cannabis as a safer substitute for harder drugs, this evidence suggests that for at least one major substance use disorder, cannabis may function as an accelerant rather than a brake.
The Implications for Patients and Policy
The Lancet Psychiatry study arrives at a pivotal moment for cannabis policy in the United States. With the Trump administration actively pursuing federal rescheduling from Schedule I to Schedule III [Quick Definition: A mid-level federal drug classification including ketamine and testosterone], and state medical programs expanding their qualifying condition lists, there is a widening gap between the pace of policy liberalization and the pace of clinical evidence.
Rescheduling to Schedule III would formally acknowledge cannabis as having accepted medical use, a classification that the Lancet findings complicate considerably. If the most common reason people use medical cannabis — mental health management — lacks supporting evidence, it raises fundamental questions about the scientific foundation underpinning expanded access programs.
For patients currently using cannabis for anxiety, depression, or PTSD, the study does not necessarily mean they should immediately stop. Individual responses to treatment vary, and the relationship between cannabis and mental health is complex. However, the research does suggest that patients should have frank conversations with their healthcare providers about evidence-based alternatives and should be aware that their improvement may be driven by expectation rather than pharmacology.
The Research Gap That Needs Filling
One of the most important conclusions from the Wilson team's work is not about what cannabis cannot do, but about how little we actually know. Forty-five years of research produced only 54 trials that met basic quality standards — a remarkably thin evidence base for a substance used medicinally by tens of millions of people.
The researchers called for dramatically expanded investment in cannabis clinical trials, particularly large-scale, well-designed studies that can definitively answer questions about efficacy and safety. Federal rescheduling could facilitate this research by removing many of the regulatory barriers that have historically limited cannabis studies in the United States, potentially turning this moment of uncertainty into an opportunity for the rigorous science that patients deserve.
Pull-Quote Suggestions:
"As cannabis rescheduling advances at the federal level and more states expand medical programs, millions of Americans are turning to cannabis specifically for mental health relief — often without rigorous evidence to support that choice."
"That means tens of millions of people across North America are using cannabis-based products to manage conditions like anxiety, depression, and PTSD — conditions for which this new research suggests cannabis provides no reliable benefit."
"Forty-five years of research produced only 54 trials that met basic quality standards — a remarkably thin evidence base for a substance used medicinally by tens of millions of people."
Why It Matters: A massive 45-year review in The Lancet Psychiatry finds medicinal cannabis ineffective for mental health conditions. Here's what patients need to know.